A case of dihydropyrimidinase deficiency incidentally detected by urine metabolome analysis

Hiroki Tsuchiya, Tomoyuki Akiyama, Tomiko Kuhara, Yoko Nakajima, Morimasa Ohse, Hiroki Kurahashi, Takema Kato, Yasuhiro Maeda, Harumi Yoshinaga, Katsuhiro Kobayashi

Research output: Contribution to journalArticle

Abstract

Dihydropyrimidinase deficiency is a rare autosomal recessive disease affecting the second step of pyrimidine degradation. It is caused by mutations in the DPYS gene. Only approximately 30 cases have been reported to date, with a phenotypical variability ranging from asymptomatic to severe neurological illness. We report a case of dihydropyrimidinase deficiency incidentally detected by urine metabolome analysis. Gas chromatography-mass spectrometry-based urine metabolomics demonstrated significant elevations of dihydrouracil and dihydrothymine, which were subsequently confirmed by a quantitative analysis using liquid chromatography-tandem mass spectrometry. Genetic testing of the DPYS gene revealed two mutations: a novel mutation (c.175G > T) and a previously reported mutation (c.1469G > A). Dihydropyrimidinase deficiency is probably underdiagnosed, considering its wide phenotypical variability, nonspecific neurological presentations, and an estimated prevalence of 2/20,000. As severe 5-fluorouracil-associated toxicity has been reported in patients and carriers of congenital pyrimidine metabolic disorders, urinary pyrimidine analysis should be considered for those who will undergo 5-fluorouracil treatment.

LanguageEnglish
JournalBrain and Development
DOIs
Publication statusAccepted/In press - Jan 1 2018

Fingerprint

Metabolome
Urine
Mutation
Fluorouracil
Metabolomics
Genetic Testing
Tandem Mass Spectrometry
Liquid Chromatography
Gas Chromatography-Mass Spectrometry
Genes
Dihydropyrimidinase Deficiency
pyrimidine
Therapeutics

Keywords

  • 5-Fluorouracil
  • DPYS gene
  • Pyrimidine metabolism
  • Screening

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Developmental Neuroscience
  • Clinical Neurology

Cite this

A case of dihydropyrimidinase deficiency incidentally detected by urine metabolome analysis. / Tsuchiya, Hiroki; Akiyama, Tomoyuki; Kuhara, Tomiko; Nakajima, Yoko; Ohse, Morimasa; Kurahashi, Hiroki; Kato, Takema; Maeda, Yasuhiro; Yoshinaga, Harumi; Kobayashi, Katsuhiro.

In: Brain and Development, 01.01.2018.

Research output: Contribution to journalArticle

Tsuchiya, Hiroki ; Akiyama, Tomoyuki ; Kuhara, Tomiko ; Nakajima, Yoko ; Ohse, Morimasa ; Kurahashi, Hiroki ; Kato, Takema ; Maeda, Yasuhiro ; Yoshinaga, Harumi ; Kobayashi, Katsuhiro. / A case of dihydropyrimidinase deficiency incidentally detected by urine metabolome analysis. In: Brain and Development. 2018.
@article{a2133052db36472782e6b167850d1c13,
title = "A case of dihydropyrimidinase deficiency incidentally detected by urine metabolome analysis",
abstract = "Dihydropyrimidinase deficiency is a rare autosomal recessive disease affecting the second step of pyrimidine degradation. It is caused by mutations in the DPYS gene. Only approximately 30 cases have been reported to date, with a phenotypical variability ranging from asymptomatic to severe neurological illness. We report a case of dihydropyrimidinase deficiency incidentally detected by urine metabolome analysis. Gas chromatography-mass spectrometry-based urine metabolomics demonstrated significant elevations of dihydrouracil and dihydrothymine, which were subsequently confirmed by a quantitative analysis using liquid chromatography-tandem mass spectrometry. Genetic testing of the DPYS gene revealed two mutations: a novel mutation (c.175G > T) and a previously reported mutation (c.1469G > A). Dihydropyrimidinase deficiency is probably underdiagnosed, considering its wide phenotypical variability, nonspecific neurological presentations, and an estimated prevalence of 2/20,000. As severe 5-fluorouracil-associated toxicity has been reported in patients and carriers of congenital pyrimidine metabolic disorders, urinary pyrimidine analysis should be considered for those who will undergo 5-fluorouracil treatment.",
keywords = "5-Fluorouracil, DPYS gene, Pyrimidine metabolism, Screening",
author = "Hiroki Tsuchiya and Tomoyuki Akiyama and Tomiko Kuhara and Yoko Nakajima and Morimasa Ohse and Hiroki Kurahashi and Takema Kato and Yasuhiro Maeda and Harumi Yoshinaga and Katsuhiro Kobayashi",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.braindev.2018.10.005",
language = "English",
journal = "Brain and Development",
issn = "0387-7604",
publisher = "Elsevier",

}

TY - JOUR

T1 - A case of dihydropyrimidinase deficiency incidentally detected by urine metabolome analysis

AU - Tsuchiya, Hiroki

AU - Akiyama, Tomoyuki

AU - Kuhara, Tomiko

AU - Nakajima, Yoko

AU - Ohse, Morimasa

AU - Kurahashi, Hiroki

AU - Kato, Takema

AU - Maeda, Yasuhiro

AU - Yoshinaga, Harumi

AU - Kobayashi, Katsuhiro

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Dihydropyrimidinase deficiency is a rare autosomal recessive disease affecting the second step of pyrimidine degradation. It is caused by mutations in the DPYS gene. Only approximately 30 cases have been reported to date, with a phenotypical variability ranging from asymptomatic to severe neurological illness. We report a case of dihydropyrimidinase deficiency incidentally detected by urine metabolome analysis. Gas chromatography-mass spectrometry-based urine metabolomics demonstrated significant elevations of dihydrouracil and dihydrothymine, which were subsequently confirmed by a quantitative analysis using liquid chromatography-tandem mass spectrometry. Genetic testing of the DPYS gene revealed two mutations: a novel mutation (c.175G > T) and a previously reported mutation (c.1469G > A). Dihydropyrimidinase deficiency is probably underdiagnosed, considering its wide phenotypical variability, nonspecific neurological presentations, and an estimated prevalence of 2/20,000. As severe 5-fluorouracil-associated toxicity has been reported in patients and carriers of congenital pyrimidine metabolic disorders, urinary pyrimidine analysis should be considered for those who will undergo 5-fluorouracil treatment.

AB - Dihydropyrimidinase deficiency is a rare autosomal recessive disease affecting the second step of pyrimidine degradation. It is caused by mutations in the DPYS gene. Only approximately 30 cases have been reported to date, with a phenotypical variability ranging from asymptomatic to severe neurological illness. We report a case of dihydropyrimidinase deficiency incidentally detected by urine metabolome analysis. Gas chromatography-mass spectrometry-based urine metabolomics demonstrated significant elevations of dihydrouracil and dihydrothymine, which were subsequently confirmed by a quantitative analysis using liquid chromatography-tandem mass spectrometry. Genetic testing of the DPYS gene revealed two mutations: a novel mutation (c.175G > T) and a previously reported mutation (c.1469G > A). Dihydropyrimidinase deficiency is probably underdiagnosed, considering its wide phenotypical variability, nonspecific neurological presentations, and an estimated prevalence of 2/20,000. As severe 5-fluorouracil-associated toxicity has been reported in patients and carriers of congenital pyrimidine metabolic disorders, urinary pyrimidine analysis should be considered for those who will undergo 5-fluorouracil treatment.

KW - 5-Fluorouracil

KW - DPYS gene

KW - Pyrimidine metabolism

KW - Screening

UR - http://www.scopus.com/inward/record.url?scp=85055518909&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055518909&partnerID=8YFLogxK

U2 - 10.1016/j.braindev.2018.10.005

DO - 10.1016/j.braindev.2018.10.005

M3 - Article

JO - Brain and Development

T2 - Brain and Development

JF - Brain and Development

SN - 0387-7604

ER -